CF PharmTech, Inc. submitted its Monthly Return for the period ended 31 May 2026 to Hong Kong Exchanges and Clearing Limited on 03 June 2026.

• Registered capital remained unchanged at 411.98 million shares with a par value of RMB1.00 per share.

• Issued share structure at month-end: – H shares: 301.01 million in issue (excluding treasury shares) and 1.22 million held in treasury, keeping total H-share issuance at 302.22 million. – Domestic shares: 109.75 million, unchanged. – Aggregate issued shares across both classes stayed at 411.98 million.

• Movements during the month: – 551,000 H shares were repurchased on 16 December 2025 and transferred to treasury in May’s ledger, reducing outstanding H shares by the same amount and increasing treasury shares to 1.22 million. No shares were cancelled.

• Public-float confirmation: the company affirmed compliance with the 24.7 percent minimum public-float requirement for its H shares as of 31 May 2026.

• Capital instruments: there were no outstanding or new share options, warrants, convertibles, or other equity-linked agreements reported for the month.

The filing was signed by Executive Director and Joint Company Secretary Zhu Yuyu, confirming adherence to all relevant listing and regulatory obligations.